Sonoma Pharmaceuticals (SNOA) Long-Term Investments (2014 - 2015)
Sonoma Pharmaceuticals' (SNOA) quarterly Long-Term Investments came in at $4.5 million in Q1 2015, down 55.29% year-on-year from $10.1 million in Q1 2014, and down 17.49% quarter-over-quarter from $5.5 million in Q4 2014.
Sonoma Pharmaceuticals (SNOA) Long-Term Investments (2014 - 2015) Analysis & Trends
Sonoma Pharmaceuticals' Long-Term Investments history runs 2 years deep, the most recent figure standing at $4.5 million for Q1 2015.
- On a quarterly basis, Long-Term Investments fell 55.29% year-over-year to $4.5 million in Q1 2015; TTM through Mar 2015 was $4.5 million, a 55.29% decrease from a year earlier, with the FY2015 full-year figure at $4.5 million, down 55.29% from the prior year.
- Long-Term Investments retreated to $4.5 million in Q1 2015 per SNOA's latest filing, from $5.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $10.2 million in Q1 2014 and bottomed at $4.5 million in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 4.54 Mn |
| Dec 31, 2014 | 5.50 Mn |
| Sep 30, 2014 | 10.15 Mn |
| Mar 31, 2014 | 10.15 Mn |